Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur S. SMILE |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study / S. SMILE in Research in Autism Spectrum Disorders, 7-2 (February 2013)
[article]
Titre : Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study Type de document : Texte imprimé et/ou numérique Auteurs : S. SMILE, Auteur ; A. DUPUIS, Auteur ; C. MACARTHUR, Auteur ; Wendy ROBERTS, Auteur ; D. FEHLINGS, Auteur Année de publication : 2013 Article en page(s) : p.391-397 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Cerebral palsy Diagnosis Co-morbidity Index. décimale : PER Périodiques Résumé : The current study aims to describe the cognitive profile, autism profile, medical and behavioral presentation of children with a dual diagnosis of cerebral palsy (CP) and autism spectrum disorder (ASD). Little is known about the dual presentation of CP and ASD. Timely diagnosis is imperative as early intervention may impact a child's developmental trajectory. The study used a cross-sectional descriptive design. We report data on cognitive profiles, ASD presenting symptoms, the time to definitive diagnosis of ASD, medical and behavioral co-morbidities in children with a dual diagnosis of CP and ASD. Seventy-two percent (72%) of children with CP + ASD had a developmental disability profile. Children were diagnosed with ASD at the median age of 66.5 months (range: 31'210 months). Repetitive behaviors were the most common ASD alerting symptom. Repetitive motor mannerisms were reported in 71% of CP + ASD population. Constipation, asthma and aggression showed highest statistical differences between CP + ASD group and CP only group. Our study has established that cognitive impairment is common amongst children with CP + ASD. ASD is diagnosed later in children with CP + ASD, than reference age of diagnosis in children with ASD. Medical and behavioral co-morbidities are common in children with CP + ASD. Clinicians need to be sensitized to the possibility of multiple diagnoses including ASD in children with cerebral palsy. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186
in Research in Autism Spectrum Disorders > 7-2 (February 2013) . - p.391-397[article] Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study [Texte imprimé et/ou numérique] / S. SMILE, Auteur ; A. DUPUIS, Auteur ; C. MACARTHUR, Auteur ; Wendy ROBERTS, Auteur ; D. FEHLINGS, Auteur . - 2013 . - p.391-397.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 7-2 (February 2013) . - p.391-397
Mots-clés : Autism spectrum disorder Cerebral palsy Diagnosis Co-morbidity Index. décimale : PER Périodiques Résumé : The current study aims to describe the cognitive profile, autism profile, medical and behavioral presentation of children with a dual diagnosis of cerebral palsy (CP) and autism spectrum disorder (ASD). Little is known about the dual presentation of CP and ASD. Timely diagnosis is imperative as early intervention may impact a child's developmental trajectory. The study used a cross-sectional descriptive design. We report data on cognitive profiles, ASD presenting symptoms, the time to definitive diagnosis of ASD, medical and behavioral co-morbidities in children with a dual diagnosis of CP and ASD. Seventy-two percent (72%) of children with CP + ASD had a developmental disability profile. Children were diagnosed with ASD at the median age of 66.5 months (range: 31'210 months). Repetitive behaviors were the most common ASD alerting symptom. Repetitive motor mannerisms were reported in 71% of CP + ASD population. Constipation, asthma and aggression showed highest statistical differences between CP + ASD group and CP only group. Our study has established that cognitive impairment is common amongst children with CP + ASD. ASD is diagnosed later in children with CP + ASD, than reference age of diagnosis in children with ASD. Medical and behavioral co-morbidities are common in children with CP + ASD. Clinicians need to be sensitized to the possibility of multiple diagnoses including ASD in children with cerebral palsy. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186 A pilot dose finding study of pioglitazone in autistic children / L. CAPANO in Molecular Autism, 9 (2018)
[article]
Titre : A pilot dose finding study of pioglitazone in autistic children Type de document : Texte imprimé et/ou numérique Auteurs : L. CAPANO, Auteur ; A. DUPUIS, Auteur ; Jessica BRIAN, Auteur ; D. MANKAD, Auteur ; L. GENORE, Auteur ; R. HASTIE ADAMS, Auteur ; S. SMILE, Auteur ; T. LUI, Auteur ; D. ODROBINA, Auteur ; J. A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : 59p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Clinical trial Cytokines Drug therapy Efficacy Inflammation Maximum tolerated dose (MTD) Physiological effects of drugs Pioglitazone Safety profile Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371
in Molecular Autism > 9 (2018) . - 59p.[article] A pilot dose finding study of pioglitazone in autistic children [Texte imprimé et/ou numérique] / L. CAPANO, Auteur ; A. DUPUIS, Auteur ; Jessica BRIAN, Auteur ; D. MANKAD, Auteur ; L. GENORE, Auteur ; R. HASTIE ADAMS, Auteur ; S. SMILE, Auteur ; T. LUI, Auteur ; D. ODROBINA, Auteur ; J. A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur . - 59p.
Langues : Anglais (eng)
in Molecular Autism > 9 (2018) . - 59p.
Mots-clés : Autism spectrum disorder Clinical trial Cytokines Drug therapy Efficacy Inflammation Maximum tolerated dose (MTD) Physiological effects of drugs Pioglitazone Safety profile Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371